SOLID BIOSCIENCES INC (SLDB) Stock Fundamental Analysis

NASDAQ:SLDB • US83422E2046

6.19 USD
+0.11 (+1.81%)
At close: Feb 13, 2026
6.19 USD
0 (0%)
After Hours: 2/13/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Taking everything into account, SLDB scores 3 out of 10 in our fundamental rating. SLDB was compared to 523 industry peers in the Biotechnology industry. While SLDB has a great health rating, there are worries on its profitability. SLDB does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year SLDB has reported negative net income.
  • SLDB had a negative operating cash flow in the past year.
  • SLDB had negative earnings in each of the past 5 years.
  • In the past 5 years SLDB always reported negative operating cash flow.
SLDB Yearly Net Income VS EBIT VS OCF VS FCFSLDB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -61.02%, SLDB is in line with its industry, outperforming 42.45% of the companies in the same industry.
  • The Return On Equity of SLDB (-76.69%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -61.02%
ROE -76.69%
ROIC N/A
ROA(3y)-52.5%
ROA(5y)-48.03%
ROE(3y)-69.2%
ROE(5y)-61.82%
ROIC(3y)N/A
ROIC(5y)N/A
SLDB Yearly ROA, ROE, ROICSLDB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SLDB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLDB Yearly Profit, Operating, Gross MarginsSLDB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • SLDB has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for SLDB has been increased compared to 5 years ago.
  • Compared to 1 year ago, SLDB has an improved debt to assets ratio.
SLDB Yearly Shares OutstandingSLDB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
SLDB Yearly Total Debt VS Total AssetsSLDB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -0.69, we must say that SLDB is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -0.69, SLDB is in line with its industry, outperforming 57.74% of the companies in the same industry.
  • SLDB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.69
ROIC/WACCN/A
WACCN/A
SLDB Yearly LT Debt VS Equity VS FCFSLDB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 6.74 indicates that SLDB has no problem at all paying its short term obligations.
  • SLDB has a Current ratio of 6.74. This is in the better half of the industry: SLDB outperforms 68.64% of its industry peers.
  • SLDB has a Quick Ratio of 6.74. This indicates that SLDB is financially healthy and has no problem in meeting its short term obligations.
  • SLDB has a better Quick ratio (6.74) than 68.83% of its industry peers.
Industry RankSector Rank
Current Ratio 6.74
Quick Ratio 6.74
SLDB Yearly Current Assets VS Current LiabilitesSLDB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 18.09% over the past year.
EPS 1Y (TTM)18.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 14.37% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y29.56%
EPS Next 2Y14.46%
EPS Next 3Y10.39%
EPS Next 5Y14.37%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLDB Yearly Revenue VS EstimatesSLDB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M 1B
SLDB Yearly EPS VS EstimatesSLDB Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -10 -20 -30 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SLDB. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SLDB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLDB Price Earnings VS Forward Price EarningsSLDB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLDB Per share dataSLDB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.46%
EPS Next 3Y10.39%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SLDB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SOLID BIOSCIENCES INC

NASDAQ:SLDB (2/13/2026, 8:00:02 PM)

After market: 6.19 0 (0%)

6.19

+0.11 (+1.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03
Earnings (Next)03-04
Inst Owners90.27%
Inst Owner Change0.35%
Ins Owners0.61%
Ins Owner Change2.23%
Market Cap482.26M
Revenue(TTM)N/A
Net Income(TTM)-167.13M
Analysts86
Price Target16.04 (159.13%)
Short Float %13.11%
Short Ratio8.89
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)5.52%
Min EPS beat(2)-7.27%
Max EPS beat(2)18.31%
EPS beat(4)1
Avg EPS beat(4)-3.66%
Min EPS beat(4)-21.61%
Max EPS beat(4)18.31%
EPS beat(8)4
Avg EPS beat(8)-2.26%
EPS beat(12)7
Avg EPS beat(12)-1.96%
EPS beat(16)9
Avg EPS beat(16)-1.49%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.26%
PT rev (3m)-0.57%
EPS NQ rev (1m)0.26%
EPS NQ rev (3m)-0.12%
EPS NY rev (1m)-0.37%
EPS NY rev (3m)-5.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.21
P/tB 2.21
EV/EBITDA N/A
EPS(TTM)-2.49
EYN/A
EPS(NY)-2.1
Fwd EYN/A
FCF(TTM)-1.71
FCFYN/A
OCF(TTM)-1.7
OCFYN/A
SpS0
BVpS2.8
TBVpS2.8
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -61.02%
ROE -76.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-52.5%
ROA(5y)-48.03%
ROE(3y)-69.2%
ROE(5y)-61.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 47.8%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.74
Quick Ratio 6.74
Altman-Z -0.69
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)70.22%
Cap/Depr(5y)55.37%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.24%
EPS Next Y29.56%
EPS Next 2Y14.46%
EPS Next 3Y10.39%
EPS Next 5Y14.37%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-50.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-43.58%
EBIT Next 3Y-22.66%
EBIT Next 5YN/A
FCF growth 1Y-20.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22.75%
OCF growth 3YN/A
OCF growth 5YN/A

SOLID BIOSCIENCES INC / SLDB FAQ

What is the fundamental rating for SLDB stock?

ChartMill assigns a fundamental rating of 3 / 10 to SLDB.


What is the valuation status of SOLID BIOSCIENCES INC (SLDB) stock?

ChartMill assigns a valuation rating of 0 / 10 to SOLID BIOSCIENCES INC (SLDB). This can be considered as Overvalued.


Can you provide the profitability details for SOLID BIOSCIENCES INC?

SOLID BIOSCIENCES INC (SLDB) has a profitability rating of 1 / 10.


What is the earnings growth outlook for SOLID BIOSCIENCES INC?

The Earnings per Share (EPS) of SOLID BIOSCIENCES INC (SLDB) is expected to grow by 29.56% in the next year.